Skip to content
NASDAQ · PHARMACEUTICAL PREPARATIONS · SMALL CAP

Abeona Therapeutics Inc. ABEO

16 fiscal years on record · USD · FY2025 reported · SEC filings only
$5.8M
$71.2M
$-84.3M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

ZEVASKYN® is manufactured at our current Good Manufacturing Practices (“cGMP”) manufacturing facility in Cleveland, Ohio. As of March 2026, we have activated 4 qualified treatment centers and are in discussions with additional centers as we continue to expand the ZEVASKYN® qualified treatment network. The Company’s development portfolio also features adeno-associated virus (“AAV”)-based gene therapies designed to treat ophthalmic diseases with high unmet need using novel AIM™ capsids.

Written from the business description in Abeona Therapeutics Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 17 March 2026. Every sentence was checked against that document before publication.

Growth

USD 5.8M
Revenue, FY2025 · full 16-year series below
Revenue $M Net income $M
FY2025 · Revenue 5.8 · Net income 71.2
25.0M50.0M-30.0M-60.0M
201020132016201920222025
Compound annual growth
3 yrs
5 yrs
10 yrs
15 yrs

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

1223 cents
of every revenue dollar became profit
Operating margin Net margin
FY2025 · Operating -1536.9% · Net 1223.1%
500%1000%-1000%-2000%-3000%
201020172025
ROE
FY2025 · ROE 70.0%
20%40%60%-100%-200%
201020172025
Three returns, three denominators.
Gross margin73.7%
Operating margin-1536.9%
Net margin1223.1%
EBITDAUSD -86.9M

Each USD of equity produced 70 cents of profit this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -84.3
-30M-60M
201020172025

Total assetsUSD 219.6M
EquityUSD 159.2M
CashUSD 78.4M
Gross debtUSD 20.0M
Net debtUSD -58.4M
Current ratio6.93×

The company holds more cash than debt.

The 16-year record

16 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
ABEO, 16-year financial record
Metric 2025202420232022202120202019201820172016201520142013201220112010
Revenue $B0.0◌0.00.00.00.0◌0.00.00.00.00.00.00.00.00.0
Operating income $B−0.1−0.1−0.0−0.1−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.1−0.1−0.0−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.0◌◌◌◌◌◌0.00.00.00.00.00.00.00.00.0
Net income $B0.1−0.1−0.1−0.0−0.1−0.1−0.1−0.1−0.0−0.0−0.0−0.00.0−0.0−0.0−0.0
Free cash flow $B−0.1−0.1−0.0−0.0−0.1−0.0−0.1−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $1.01−1.55−2.53−5.53−0.86−0.91−1.51−1.19−0.66−0.64−0.53−15.263.04−0.52−0.22−0.60
Dividend / sh $◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌◌
Payout % — not applicable: no dividend————————————————
ROE %70.0−216.6−260.6−114.8−117.2−60.0−48.8−37.3−20.3−26.2−40.1—————
Shares out B0.060.050.030.020.150.100.080.050.050.04◌◌◌◌◌◌

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 63 reconciliationsAUDITED

Reconciled in 16 of the 16 fiscal years we could check. Six checks were skipped: the balance sheet is not tagged before 2010. Four checks were skipped: the share count is not tagged before 2011. Three checks were skipped: revenue is not tagged before 2010.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivityPharmaceutical Preparations
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categorysmaller reporting company
Data on record since2010

Share this section

Download image